Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Odevixibat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 known ✓ | Q12908 | 2/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Odevixibat SCHEMBL19046540 | 1.00 | NR1H4 (1.00) | NR1H4KMT2AATMSLC10A2 | |
| Odevixibat SCHEMBL25794588 | 1.00 | NR1H4 (1.00) | NR1H4KMT2AATMSLC10A2 | |
| Odevixibat SCHEMBL17733623 | 1.00 | NR1H4 (1.00) | NR1H4KMT2AATMSLC10A2 | |
| Odevixibat SCHEMBL31121705 | 1.00 | NR1H4 (1.00) | NR1H4KMT2AATMSLC10A2 | |
| Odevixibat SCHEMBL16414427 | 1.00 | NR1H4 (1.00) | NR1H4KMT2AATMSLC10A2 | |
| SCHEMBL20260213 | 0.99 | NR1H4 (0.98) | NR1H4KMT2AATMSLC10A2 | |
| SCHEMBL4566711 | 0.96 | NR1H4 (0.93) | NR1H4SLC10A2 | |
| SCHEMBL19046549 | 0.96 | NR1H4 (0.93) | NR1H4SLC10A2 | |
| SCHEMBL918882 | 0.96 | NR1H4 (0.93) | NR1H4SLC10A2 | |
| SCHEMBL2697206 | 0.96 | NR1H4 (0.92) | NR1H4KMT2AATMSLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 846 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724071-A1 | NOVEL USE OF AN ILEAL BILE ACID TRANSPORTER INHIBITOR FOR THE TREATMENT OF PRURITUS | GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) | 2026-04-15 | — | — | EP | claimed |
| US-20260091040-A1 | Treating Progressive Familial Intrahepatic Cholestasis (PFIC) with IBAT Inhibitors | ALBIREO AB (SE) | 2026-04-02 | — | — | US | claimed |
| US-12508234-B2 | Pharmaceutical formulation of odevixibat | ALBIREO AB (SE) | 2025-12-30 | — | — | US | claimed |
| US-12447156-B2 | Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors | ALBIREO AB (SE) | 2025-10-21 | — | — | US | claimed |
| EP-4629997-A1 | ASBT INHIBITORS IN THE TREATMENT OF RENAL DISEASES | Albireo AB (SE) | 2025-10-15 | — | — | EP | claimed |
| EP-4630112-A1 | COCRYSTALS OF ODEVIXIBAT | Albireo AB (SE) | 2025-10-15 | — | — | EP | claimed |
| EP-4590314-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | Astellas Gene Therapies, Inc. (US) | 2025-07-30 | — | — | EP | claimed |
| EP-4566590-A1 | TASTE-MASKING MICROSPHERE, PREPARATION PROCESS THEREFOR, AND USE THEREOF | Harbin Kanon Pharmaceutical Co., Ltd (CN) | 2025-06-11 | — | — | EP | claimed |
| EP-4511038-A1 | SUBCUTANEOUS ADMINISTRATION OF AN ASBT INHIBITOR | Albireo AB (SE) | 2025-02-26 | — | — | EP | claimed |
| US-20250019354-A1 | Crystal Modifications of Odevixibat | ALBIREO AB (SE) | 2025-01-16 | — | — | US | claimed |
| US-20050171204-A1 | Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) | ASTRAZENECA AB (SE) | 2005-08-04 | — | — | US | claimed |
| US-20050131068-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | claimed |
| EP-1539120-A1 | COMBINATION OF AN IBAT INHIBITOR AND A METAL SALT FOR THE TREATMENT OF DIARRHOEA | Astrazeneca AB (SE) | 2005-06-15 | — | — | EP | claimed |
| US-20050113362-A1 | Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) | ASTRAZENECA AB R & D HEADQUARTERS - GLOBAL IINTELLECTUAL PROPERT (SE) | 2005-05-26 | — | — | US | claimed |
| WO-2004089350-A1 | USE OF AN IBAT INHIBITOR FOR THE TREATMENT OF PROPHYLAXIS OF CONSTIPATION | ASTRAZENECA AB (SE) | 2004-10-21 | — | — | WO | claimed |
| EP-1458677-A1 | 3-PHENYL-2-ARYLALKYLTHIOPROPIONIC ACID DERIVATIVES AS SELECTIVE AGONISTS OF PPAR-ALPHA | Astrazeneca AB (SE) | 2004-09-22 | — | — | EP | claimed |
| EP-1458672-A1 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA(PPAR) | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | claimed |
| WO-2004006899-A1 | COMBINATION OF AN IBAT INHIBITOR AND A METAL SALT FOR THE TREATMENT OF DIARRHOEA | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | claimed |
| WO-2003051826-A1 | 3-PHENYL-2-ARYLALKYLTHIOPROPIONIC ACID DERIVATIVES AS SELECTIVE AGONISTS OF PPAR-ALPHA | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | claimed |
| WO-2003051822-A1 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR) | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131068-A1 | Therapeutic agents | GPR119, INSR, LIPA | SLC10A2 175/4885NR1H4 94/4885KMT2A 3639/4885 |
| US-12508234-B2 | Pharmaceutical formulation of odevixibat | SLC10A1, ABCB11, SLC10A2 | SLC10A2 3/4885NR1H4 39/4885KMT2A 3186/4885 |
| US-12447156-B2 | Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885NR1H4 4/4885KMT2A 1279/4885 |
| US-20050113362-A1 | Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) | PPARA, PPARD, PPARG | SLC10A2 434/4885NR1H4 33/4885KMT2A 2757/4885 |
| US-20260091040-A1 | Treating Progressive Familial Intrahepatic Cholestasis (PFIC) with IBAT Inhibitors | SLC10A2, SLC10A1, ABCB11 | SLC10A2 1/4885NR1H4 26/4885KMT2A 2489/4885 |
| US-20050171204-A1 | Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) | PPARA, PPARD, PPARG | SLC10A2 209/4885NR1H4 46/4885KMT2A 3897/4885 |
| US-20250019354-A1 | Crystal Modifications of Odevixibat | OR10J3, SULT1E1, OPRD1 | SLC10A2 1148/4885NR1H4 841/4885KMT2A 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.